Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today released the new Genedata Expressionist® MSX for academic proteomics and metabolomics research. Announced at the HUPO 11th Annual World Congress, Expressionist MSX offers the same superior algorithms and data visualization capabilities available in the enterprise-level Genedata Expressionist for Mass Spectrometry (MS). Genedata Expressionist for MS is used for high-throughput experiments by leading pharma and crop-science companies. Competitively priced, Expressionist MSX is downloaded directly via the Internet and immediately installs for an unmatched user experience in academic research. Genedata will demonstrate the new Genedata Expressionist MSX at HUPO 2012 at the Hynes Convention Center (Sept. 10 – 13; Booth 402).
“By significantly reducing the cost barrier to MS data analysis, Expressionist MSX provides previously unavailable tools to academic researchers,” noted Dr. Peter Askovich, a senior scientist with the Seattle Biomedical Research Institute. “Expressionist MSX makes in-depth analysis of complex mass spectrometry experiments affordable and allows scientists to analyze their data with the same rigor, algorithmic power, and high-quality data visualization provided in Genedata’s enterprise solution.”
Mass Spectrometry Data Analysis in Minutes vs. Days
The result of nearly a decade of proven customer success in MS data analysis, Expressionist MSX analyzes proteomics and metabolomics data for a variety of applications directly from the instrument. It downloads from a dedicated website in a Windows-executable file and is up and running in minutes. With native vendor support, Expressionist MSX features built-in, proven statistical tools borrowed from Genedata Expressionist for MS. The validated best-of-breed algorithms in Expressionist MSX significantly reduce the number of false-positive and false-negative biomarkers. Moreover, its powerful and interactive data visualization tools enable researchers to explore and validate MS data and results in completely new ways.
Expressionist MSX is packaged with support for a variety of proteomic and metabolomic MS setups such as
The system can be applied in a variety of studies including: biomarker discovery and validation; protein profiling; peptide identification and quantification; protein-protein interaction; metabolic profiling within drug development; and plant breeding.
“With Genedata Expressionist MSX, we specifically want to support academia’s innovative research in mass spectrometry by enabling many new and important applications,” noted Dr. Othmar Pfannes, CEO of Genedata. “Based on proven algorithmic superiority and ease-of-use capabilities of Genedata Expressionist, Expressionist MSX helps scientists to capitalize on the quality and power of enterprise-class software as they open doors to new discoveries in the life sciences.”
System Requirements and Availability
Genedata Expressionist MSX requires a standard Windows environment with a minimum of 4GB of RAM. It can be downloaded with a free trial license from www.expressionist-msx.com. Downloads are now available.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.